Publication Listing for the MeSH term Prostate cancer. Found 50 abstracts
paginateCrook JM, Zhang P, Pisansky TM, Trabulsi EJ, Amin MB, Bice W, Morton G, Pervez N, Vigneault E, Catton C, Michalski J, Roach M, Beyer D, Jani A, Horwitz E, Donavanik V, Sandler H. A Prospective Phase 2 Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Cancer After External Beam Radiation Therapy (NRG Oncology/RTOG-0526). Int J Radiat Oncol Biol Phys. 2019 Feb;103(2):335-43. PMCID: PMC6368223 |
Gershman B, Maroni P, Tilburt JC, Volk RJ, Konety B, Bennett CL, Kutikov A, Smaldone MC, Chen V, Kim SP. A national survey of radiation oncologists and urologists on prediction tools and nomograms for localized prostate cancer. World journal of urology. 2019 Oct;37(10):2099-108. |
Hallemeier CL, Zhang P, Pisansky TM, Hanks GE, McGowan DG, Roach M, Zeitzer KL, Firat SY, Husain SM, D'Souza DP, Souhami L, Parliament MB, Rosenthal SA, Lukka HR, Rotman M, Horwitz EM, Miles EF, Paulus R, Sandler HM. Prostate-specific antigen after neoadjuvant androgen suppression in prostate cancer patients receiving short-term androgen suppression and external beam radiotherapy: pooled analysis of four NRG Oncology RTOG randomized clinical trials. Int J Radiat Oncol Biol Phys. 2019 Aug;104(5):1057-65. PMCID: PMC6646073 |
Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM. Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902. Radiother Oncol. 2019 Sep 17;. |
Joshi SS, Handorf ER, Sienko D, Zibelman M, Uzzo RG, Kutikov A, Horwitz EM, Smaldone MC, Geynisman DM. Treatment Facility Volume and Survival in Patients with Advanced Prostate Cancer. European urology oncology. 2019 Jul 17;. |
Karpova Y, Wu C, Divan A, McDonnell ME, Hewlett E, Makhov P, Gordon J, Ye M, Reitz AB, Childers WE, Skorski T, Kolenko V, Tulin AV. Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. Biochemical pharmacology. 2019 Sep;167:149-62. PMCID: PMC6702078 |
Page EC, Bancroft EK, Brook MN, Assel M, Hassan Al Battat M, Thomas S, Taylor N, Chamberlain A, Pope J, Raghallaigh HN, Evans DG, Rothwell J, Maehle L, Grindedal EM, James P, Mascarenhas L, McKinley J, Side L, Thomas T, van Asperen C, Vasen H, Kiemeney LA, Ringelberg J, Jensen TD, Osther PJ, Helfand BT, Genova E, Oldenburg RA, Cybulski C, Wokolorczyk D, Ong KR, Huber C, Lam J, Taylor L, Salinas M, Feliubadalo L, Oosterwijk JC, van Zelst-Stams W, Cook J, Rosario DJ, Domchek S, Powers J, Buys S, O'Toole K, Ausems M, Schmutzler RK, Rhiem K, Izatt L, Tripathi V, Teixeira MR, Cardoso M, Foulkes WD, Aprikian A, van Randeraad H, Davidson R, Longmuir M, Ruijs MW, Helderman van den Enden A, Adank M, Williams R, Andrews L, Murphy DG, Halliday D, Walker L, Liljegren A, Carlsson S, Azzabi A, Jobson I, Morton C, Shackleton K, Snape K, Hanson H, Harris M, Tischkowitz M, Taylor A, Kirk J, Susman R, Chen-Shtoyerman R, Spigelman A, Pachter N, Ahmed M, Ramon YC, Zgajnar J, Brewer C, Gadea N, Brady AF, van Os T, Gallagher D, Johannsson O, Donaldson A, Barwell J, Nicolai N, Friedman E, Obeid E, Greenhalgh L, Murthy V, Copakova L, Saya S, McGrath J, Cooke P, Ronlund K, Richardson K, Henderson A, Teo SH, Arun B, Kast K, Dias A, Aaronson NK, Ardern-Jones A, Bangma CH, Castro E, Dearnaley D, Eccles DM, Tricker K, Eyfjord J, Falconer A, Foster C, Gronberg H, Hamdy FC, Stefansdottir V, Khoo V, Lindeman GJ, Lubinski J, Axcrona K, Mikropoulos C, Mitra A, Moynihan C, Rennert G, Suri M, Wilson P, Dudderidge T, Offman J, Kote-Jarai Z, Vickers A, Lilja H, Eeles RA. Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. Eur Urol. 2019 Sep 16;76(6):831-42. PMCID: PMC6880781 |
Ramamurthy C, Handorf EA, Correa AF, Beck JR, Geynisman DM. Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naive prostate cancer. Urol Oncol. 2019 Oct;37(10):688-95. |
Sandler KA, Cook RR, Ciezki JP, Ross AE, Pomerantz MM, Nguyen PL, Shaikh T, Tran PT, Stock RG, Merrick GS, Demanes DJ, Spratt DE, Abu-Isa EI, Wedde TB, Lilleby W, Krauss DJ, Shaw GK, Alam R, Reddy CA, Song DY, Klein EA, Stephenson AJ, Tosoian JJ, Hegde JV, Yoo SM, Fiano R, D'Amico AV, Nickols NG, Aronson WJ, Sadeghi A, Greco SC, Deville C, McNutt T, DeWeese TL, Reiter RE, Said JW, Steinberg ML, Horwitz EM, Kupelian PA, King CR, Kishan AU. Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis. Eur Urol. 2019 Apr 13;. |
Tagai EK, Miller SM, Kutikov A, Diefenbach MA, Gor RA, Al-Saleem T, Chen DY, Fleszar S, Roy G. Prostate Cancer Patients' Understanding of the Gleason Scoring System: Implications for Shared Decision-Making. Journal of cancer education : the official journal of the American Association for Cancer Education. 2019 Jan 15;34(3):441-5. PMCID: PMC6557691 |
Kim AH, Konety B, Chen Z, Schumacher F, Kutikov A, Smaldone M, Abouassaly R, Khanna A, Kim SP. Comparative Effectiveness of Local and Systemic Therapy for T4 Prostate Cancer. Urology. 2018 Oct;120:173-9. |
Oliver JS, Allen RS, Eichorst MK, Mieskowski L, Ewell PJ, Payne-Foster P, Ragin C. A pilot study of prostate cancer knowledge among African American men and their health care advocates: implications for screening decisions. Cancer causes & control : CCC. 2018 Jul;29(7):699-706. PMCID: PMC6301016 |
Shafi AA, Schiewer MJ, de Leeuw R, Dylgjeri E, McCue PA, Shah N, Gomella LG, Lallas CD, Trabulsi EJ, Centenera MM, Hickey TE, Butler LM, Raj G, Tilley WD, Cukierman E, Knudsen KE. Patient-derived Models Reveal Impact of the Tumor Microenvironment on Therapeutic Response. European urology oncology. 2018 Sep;1(4):325-37. PMCID: PMC6241309 |
Warner WA, Lee TY, Fang F, Llanos AA, Bajracharya S, Sundaram V, Badal K, Sookdeo VD, Roach V, Lamont-Greene M, Ragin C, Slovacek S, Ramsoobhag K, Brown J, Rebbeck TR, Maharaj R, Drake BF. The burden of prostate cancer in Trinidad and Tobago: one of the highest mortality rates in the world. Cancer causes & control : CCC. 2018 Jul;29(7):685-97. PMCID: PMC5999193 |
Wong YN, Manola J, Hudes GR, Roth BJ, Moul JW, Barsevick AM, Scher RM, Volk MJ, Vaughn DJ, Williams SD, Fisch MJ, Cella D, Carducci MA, Wilding G. Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial. Clin Genitourin Cancer. 2018 Apr;16(2):e315-e322. PMCID: PMC5975965 |
Dubey B, Jackson M, Zeigler-Johnson C, Devarajan K, Flores-Obando RE, McFarlane-Anderson N, Tulloch-Reid M, Aiken W, Kimbro K, Jones D, Kidd LR, Ragin C. Inflammation polymorphisms and prostate cancer risk in Jamaican men: Role of obesity/body size. Gene. 2017 Sep 10;636:96-102. PMCID: PMC5645041 |
Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 Apr;35(4):125-34. |
Metcalfe MJ, Smaldone MC, Lin DW, Aparicio AM, Chapin BF. Role of radical prostatectomy in metastatic prostate cancer: A review. Urol Oncol. 2017 Apr;35(4):125-34. |
Turner RM, Yecies TS, Yabes JG, Ristau BT, Woldemichael E, Davies BJ, Jacobs BL, Nelson JB. Biopsy Perineural Invasion in Prostate Cancer Patients Who Are Candidates for Active Surveillance by Strict and Expanded Criteria. Urology. 2017 Apr;102:173-7. PMCID: PMC5376357 |
Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer. Radiother Oncol. 2016 Nov;121(2):294-8. |
O'Malley DM, Hudson SV, Ohman-Strickland PA, Bator A, Lee HS, Gundersen DA, Miller SM. Follow-up Care Education and Information: Identifying Cancer Survivors in Need of More Guidance. Journal of Cancer Education. 2016 Mar;31(1):63-9. PMCID: PMC4475492 |
Shaikh T, Wang L, Ruth K, Hallman M, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. The impact of trainee involvement on outcomes in low-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2016 Jan 29;15(2):156-62. PMCID: PMC4789160 |
Zaorsky NG, Shaikh T, Murphy CT, Hallman MA, Hayes SB, Sobczak ML, Horwitz EM. Comparison of outcomes and toxicities among radiation therapy treatment options for prostate cancer. Cancer Treat Rev. 2016 Jun 17;48:50-60. |
Aiken WD, Jones KS, Ragin C, James K. Rural-urban differences in the clinico-pathologic profiles of Jamaican men with prostate cancer. Infect Agent Cancer. 2015 Jan;10:32. PMCID: 4584435 |
Hall MJ, Ruth KJ, Chen DY, Gross LM, Giri VN. Interest in genomic SNP testing for prostate cancer risk: a pilot survey. Hered Cancer Clin Pract. 2015 Jan;13(1):11. PMCID: 4396119 |
Haseebuddin M, Smaldone MC. Treatment of localized prostate cancer in elderly patients. Gland Surg. 2015 Aug;4(4):283-7. PMCID: PMC4523629 |
Martin JM, Handorf EA, Price RA, Cherian G, Buyyounouski MK, Chen DY, Kutikov A, Johnson ME, Ma CC, Horwitz EM. Comparison of testicular dose delivered by intensity-modulated radiation therapy (IMRT) and volumetric-modulated arc therapy (VMAT) in patients with prostate cancer. Medical Dosimetry. 2015 Jan;40(3):186-9. PMCID: 4500753 |
Miller SM, Hudson SV, Hui SK, Diefenbach MA, Fleisher L, Raivitch S, Belton T, Roy G, Njoku A, Scarpato J, Viterbo R, Buyyounouski M, Denlinger C, Miyamoto C, Reese A, Baman J. Development and preliminary testing of PROGRESS: a Web-based education program for prostate cancer survivors transitioning from active treatment. Journal of Cancer Survivorship. 2015 Sep;9(3):541-53. PMCID: 4537811 |
Shaikh T, Zaorsky NG, Ruth K, Chen DY, Greenberg RE, Li J, Crawford K, Horwitz EM. Is it necessary to perform week three dosimetric analysis in low-dose-rate brachytherapy for prostate cancer when day 0 dosimetry is done? A quality assurance assessment. Brachytherapy. 2015 Jan;14(3):316-21. PMCID: 4424094 |
Zaorsky NG, Palmer JD, Hurwitz MD, Keith SW, Dicker AP, Den RB. What is the ideal radiotherapy dose to treat prostate cancer? A meta-analysis of biologically equivalent dose escalation. Radiother Oncol. 2015 May 28;115(3):295-300. |
Bagshaw H, Ruth K, Horwitz EM, Chen DY, Buyyounouski MK. Does family history of prostate cancer affect outcomes following radiotherapy?. Radiotherapy and Oncology. 2014 Feb;110(2):229-34. PMCID: 3991234 |
Handorf E, Crumpler N, Gross L, Giri VN. Prevalence of the HOXB13 G84E Mutation Among Unaffected Men with a Family History of Prostate Cancer. Journal of Genetic Counseling. 2014 Jun;23(3):371-6. PMCID: PMC4028414 |
Yamoah K, Eldredge-Hindy HB, Zaorsky NG, Palmer JD, Doyle LA, Sendecki JA, Hesney AA, Harper L, Repka M, Showalter TN, Hurwitz MD, Dicker AP, Den RB. Large prostate gland size is not a contraindication to low-dose-rate brachytherapy for prostate adenocarcinoma. Brachytherapy. 2014 Sep;13(5):456-64. |
Davis BJ, Horwitz EM, Lee WR, Crook JM, Stock RG, Merrick GS, Butler WM, Grimm PD, Stone NN, Potters L, Zietman AL, Zelefsky MJ. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherapy. 2012 Jan;11(1):6-19. PMCID: not NIH funded |
Turaka A, Buyyounouski MK, Hanlon AL, Horwitz EM, Greenberg RE, Movsas B. Hypoxic Prostate/Muscle PO2 Ratio Predicts for Outcome in Patients With Localized Prostate Cancer: Long-Term Results. International Journal of Radiation Oncology Biology Physics. 2012 Mar;82(3):E433-E439. PMCID: not NIH funded |
Hamstra DA, Bae K, Pilepich MV, Hanks GE, Grignon DJ, McGowan DG, Roach M, Lawton C, Lee RJ, Sandler H. OLDER AGE PREDICTS DECREASED METASTASIS AND PROSTATE CANCER-SPECIFIC DEATH FOR MEN TREATED WITH RADIATION THERAPY: META-ANALYSIS OF RADIATION THERAPY ONCOLOGY GROUP TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Dec;81(5):1293-301. PMCID: NIHMS285956 |
Rodrigues G, Bae K, Roach M, Lawton C, Donnelly B, Grignon D, Hanks G, Porter A, Lepor H, Sandler H. IMPACT OF ULTRAHIGH BASELINE PSA LEVELS ON BIOCHEMICAL AND CLINICAL OUTCOMES IN TWO RADIATION THERAPY ONCOLOGY GROUP PROSTATE CLINICAL TRIALS. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):445-52. PMCID: PMC2952349 |
Sharma NK, Li TY, Chen DY, Pollack A, Horwitz EM, Buyyounouski MK. INTENSITY-MODULATED RADIOTHERAPY REDUCES GASTROINTESTINAL TOXICITY IN PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2011 Jun;80(2):437-44. PMCID: PMC2909627 |
Michalski JM, Lawton C, El Naqa I, Ritter M, O'Meara E, Seider MJ, Lee WR, Rosenthal SA, Pisansky T, Catton C, Valicenti RK, Zietman AL, Bosch WR, Sandler H, Buyyounouski MK, Menard C. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radation therapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2010 Feb;76(2):361-8. PMCID: PMC2847420 |
Roach M, Bae K, Lawton C, Donnelly BJ, Grignon D, Hanks GE, Porter A, Lepor H, Venketesan V, Sandler H. BASELINE SERUM TESTOSTERONE IN MEN TREATED WITH ANDROGEN DEPRIVATION THERAPY AND RADIOTHERAPY FOR LOCALIZED PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2010 Dec;78(5):1314-22. PMCID: PMCID: PMC2920356 [Available on 2011/12/1] |
Sharma NK, Cohen RJ, Eade TN, Buyyounouski MK, Uzzo RG, Li JS, Crawford K, Chen DY, McNeeley S, Horwitz EM. An intraoperative real-time sleeved seed technique for permanent prostate brachytherapy. Brachytherapy. 2010 Apr;9(2):126-30. PMCID: not NIH funded |
Thames HD, Kuban D, Levy LB, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. The role of overall treatment time in the outcome of radiotherapy of prostate cancer: An analysis of biochemical failure in 4839 men treated between 1987 and 1995. Radiotherapy and Oncology. 2010 Jul;96(1):6-12. PMCID: Not required |
Dotan E, Cohen SJ, Alpaugh KR, Meropol NJ. Circulating Tumor Cells: Evolving Evidence and Future Challenges. The oncologist. 2009 Jan;14(11):1070-82. PMCID: not NIH funded |
Lawton CA, Michalski J, El-Naqa I, Buyyounouski MK, Lee WR, Menard C, O'Meara E, Rosenthal SA, Ritter M, Seider M. RTOG GU RADIATION ONCOLOGY SPECIALISTS REACH CONSENSUS ON PELVIC LYMPH NODE VOLUMES FOR HIGH-RISK PROSTATE CANCER. International Journal of Radiation Oncology Biology Physics. 2009 Jun;74(2):383-7. PMCID: PMC2905150 |
Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR Appropriateness Criteria (R) on External Beam Radiation Therapy Treatment Planning for Clinically Localed Prostate Cancer Expert Panel on Radiation Oncology-Prostate. International Journal of Radiation Oncology Biology Physics. 2009 Jul;74(3):667-72. |
Zhang M, Ho A, Hammond EH, Suzuki Y, Bermudez RS, Lee RJ, Pilepich M, Shipley WU, Sandler H, Khor LY, Pollack A, Chakravarti A. Prognostic value of surviving in locally advanced prostate cancer: study based on RTOG 8610. International Journal of Radiation Oncology Biology Physics. 2009 Mar;73(4):1033-42. PMCID: PMC 2678565 |
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, Smith MR. Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92-02. European Urology. 2008 Oct;54(4):816-24. |
Horwitz EM. Does addition of 6 months' androgen suppression to radiotherapy prolong survival of men with prostate cancer?. Nature Clinical Practice Urology. 2005 Jan;2(1):16-7. |
Xiong W, Li J, Ma CM. Effect of patient variation on standard- and hypo-fractionated radiotherapy of prostate cancer. Physics in Medicine and Biology. 2005 Jan;50(7):1483-92. |
Hanks GE, Krall JM, Pilepich MV, Asbell SO, Perez CA, Rubin P, Sause WT, Doggett RL. Comparison of pathologic and clinical evaluation of lymph nodes in prostate cancer: Implications of RTOG data for patient management and trial design and stratification. International Journal of Radiation Oncology Biology Physics. 1992 Jan;23(2):293-8. |
MeSH cloud from publications including the MeSH term Prostate cancer
Prostate cancer
Brachytherapy
Radiation therapy
Radiotherapy
phase-iii trial
radiotherapy
Radiation
Clinical trials
Male
Prostatic Neoplasms
THERAPY
neoadjuvant
prostate cancer
radical prostatectomy
Breast cancer
TRIAL
Radiotherapy Dosage
Cytoreduction
Treatment of primary tumor
adjuvant
Dosimetry
androgen deprivation
Family history
Quality of life
Prognostic factors
Survivorship
Prostatectomy
competing risk
Technology
Treatment Outcome
methods
locally advanced-carcinoma
Cancer survival
Hormonal therapy
external-beam radiotherapy
androgen suppression
Surgery in metastatic
Radical prostatectomy
Local treatment
Quality assurance
radiation-therapy
Prostate
Surgery in systemic
carcinoma
Cytoreductive radical prostatectomy
Shared decision-making
po-2
Low-dose-rate brachytherapy
SECONDARY ANALYSIS
local recurrence
Cancer screening
antigen
secondary
Early detection of cancer
Genetic mutations
Sleeved seeds
risk
Tumors
IN-VIVO
LDR
Intraoperative planning
Patient variation
Upgrading
antiandrogen
Facility volume
African American
local-control
migration
External beam radiation therapy
randomized trial
adjuvant radiotherapy
Colon cancer
analysis
level
Hypofractionated
Cost-effectiveness
local therapy
blood
T4
Dose escalation
DEPRIVATION
Volumetric-modulated arc therapy
Perineural invasion
interstitial-brachytherapy
Adult
Gleason score
INTENSITY-MODULATED RADIOTHERAPY
Distant metastasis
GASTRIC CARCINOMAS
HEPATOCELLULAR-CARCINOMA
Middle Aged
Oncology
dosimetric analysis
surgery
Chemotherapy
Prostate cancer knowledge
Gleason grade group 5
Radiotherapy dose fractionation
Lymph node evaluation
Salvage low dose rate brachytherapy
ORGAN MOTION
progression-free
algorithm
Waist to hip ratio
Outcomes
IRRADIATION
Testis
BODY-COMPOSITION
Risk assessment
Rural
SPLICE VARIANTS
patient care
Fractionation
lymph node
Cancer in populations of African ancestry
Radical Prostatectomy
Genetics & Heredity
Androgen suppression
hormonal-therapy
CONFORMAL RADIOTHERAPY
Parameter estimation
Postoperative
Parp-1
Lymphography
Training
Trinidad and Tobago
radiation
Target volumes
Radiation Absorption
CLINICAL TARGET VOLUME
ASSOCIATION
BRCA1
MESSENGER-RNA
definitive radiotherapy
Personalized medicine
Intensity-modulated radiotherapy
CARRIERS
Radiation Exposure
Brca1
CARCINOMA
hypofractionation
Serum testosterone
Radiation Protection
quality
Tumor microenvironment
replacement therapy
conformal radiation-therapy
survival
Poly(ADP-ribose)
predict pathological stage